公开(公告)号：US20240350576A1

公开(公告)日：2024-10-24

申请号：US18618666

申请日：2024-03-27

申请人： AMOREPACIFIC CORPORATION

发明人： Hyun Woo JEONG ,  Jinoh Chung ,  Wanki Kim ,  Jong Hwa Roh

IPC分类号： A61K36/82 ,  A61K38/01

CPC分类号： A61K36/82 ,  A61K38/011

摘要： The present disclosure relates to a method for lowering blood sugar including administering an effective amount of a green tea peptide composition to a subject in need thereof, and specifically, the green tea peptide composition according to the present disclosure exhibits a blood sugar-lowering effect through excellent stimulation of glucose transport in adipocytes, inhibition of gluconeogenesis in hepatocytes, and DPP-4 inhibitory activity, and can be applied to various health functional food compositions and pharmaceutical compositions.

公开(公告)号：US20230355704A1

公开(公告)日：2023-11-09

申请号：US18330109

申请日：2023-06-06

申请人： Nuritas Limited

发明人： Nora KHALDI ,  Cyril Lopez ,  Alessandro Adelfio

IPC分类号： A61K8/64 ,  A61F13/00 ,  A61Q19/08 ,  C12N9/02 ,  A61P17/02 ,  A61K38/01 ,  C07K14/415 ,  A61P35/00 ,  A61K9/00

CPC分类号： A61K38/01 ,  A61F13/00063 ,  A61K8/64 ,  A61K9/0014 ,  A61K38/011 ,  A61P17/02 ,  A61P35/00 ,  A61Q19/08 ,  C07K14/415 ,  C12N9/0069 ,  C12Y113/11012 ,  A61K38/00

摘要： A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQ ID NO’s: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQ ID NO’s: 15 to 505, and 546 to 704.

公开(公告)号：US20230241153A1

公开(公告)日：2023-08-03

申请号：US18164368

申请日：2023-02-03

申请人： GOWEY RESEARCH GROUP, PLLC

发明人： Brandie Gowey

IPC分类号： A61K38/01 ,  A61K33/04 ,  A61K31/714 ,  A61K33/06 ,  A61K38/06 ,  A61K36/185 ,  A61K38/16

CPC分类号： A61K38/011 ,  A61K33/04 ,  A61K31/714 ,  A61K33/06 ,  A61K38/063 ,  A61K36/185 ,  A61K38/162

摘要： The fields of virology, oncology, and primary care need a drug that can upregulate expression of genes responsible for viral and abnormal cell clearance, such as p53 and those associated with or within the RNA interference (RNAi) process. It is well-known that cellular responses to viral genes and proteins, and indeed that of precancerous or cancerous cells, require the mechanistic efforts via p53 and the RNAi. Without the p53/RNAi activities, viral load and abnormal cell presence may remain or create disease processes and symptoms. The present invention features compositions (e.g., Sarravis® Core) and methods that allow for a decrease in viral and/or cancer cell expression through up regulation of RNAi, p53, and associated cofactors.

公开(公告)号：US10010574B2

公开(公告)日：2018-07-03

申请号：US11572944

申请日：2004-07-31

申请人： Sung Su Kim ,  Cheol Hyoung Park ,  Sang-Hyung Lee ,  Wan-Seok Joo ,  Won Bok Lee

发明人： Sung Su Kim ,  Cheol Hyoung Park ,  Sang-Hyung Lee ,  Wan-Seok Joo ,  Won Bok Lee

IPC分类号： A61P25/28 ,  A61P25/16 ,  A61K38/01 ,  C07K14/435

CPC分类号： A61K38/011 ,  C07K14/43586

摘要： A silk peptide having neuroprotective and neurofunctional activities and its preparation method are discussed. One method relates to preparing silk protein preferably having neuroprotective activity with weight average molecular weight of 200-100,000 by hydrolysis of silk fibroin; also discussed are a composition for preventing or treating brain disease comprising silk peptide and pharmaceutically acceptable carrier, and a composition for improving brain function.

公开(公告)号：US20170304371A1

公开(公告)日：2017-10-26

申请号：US15497134

申请日：2017-04-25

申请人： KARYNG, LLC

发明人： SUSAN GOLDSBERRY ,  KARYN GROSSMAN

IPC分类号： A61K35/614 ,  A61K36/899 ,  A61K36/87 ,  A61K36/82 ,  A61K36/575 ,  A61K36/28 ,  A61K31/4166 ,  A61K36/9066 ,  A61K31/045

CPC分类号： A61K36/28 ,  A61K8/9783 ,  A61K8/9789 ,  A61K9/0014 ,  A61K31/7004 ,  A61K31/704 ,  A61K36/185 ,  A61K36/51 ,  A61K38/011 ,  A61K38/39 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24 ,  A61K47/26 ,  A61K47/46 ,  A61Q19/08 ,  A61K2300/00

摘要： An active constituent complex includes an active carrier, an anti-inflammatory agent, a collagen synthesis enhancer, an anti-wrinkle agent, and a keratinocyte growth factor stimulant. The active constituent complex may be incorporated into a skincare composition, such as for topical application to human skin, for promoting skin repair and restructure, and for treating skin conditions.

公开(公告)号：US20170165297A1

公开(公告)日：2017-06-15

申请号：US15441658

申请日：2017-02-24

申请人： ABBOTT LABORATORIES

发明人： Suzette Pereira ,  Sean Garvey ,  Neile Edens

IPC分类号： A61K33/30 ,  A61K31/353 ,  A61K36/82 ,  A61K36/48 ,  A61K38/01 ,  A23L33/00 ,  A23L2/66 ,  A23L33/105 ,  A23L33/16 ,  A23L33/175 ,  A23L33/19 ,  A61K9/00 ,  A61K38/39

CPC分类号： A61K33/30 ,  A23L2/66 ,  A23L33/105 ,  A23L33/16 ,  A23L33/17 ,  A23L33/175 ,  A23L33/19 ,  A23L33/195 ,  A23L33/40 ,  A23V2002/00 ,  A61K9/0095 ,  A61K31/353 ,  A61K35/20 ,  A61K36/48 ,  A61K36/82 ,  A61K38/011 ,  A61K38/018 ,  A61K38/39 ,  A61K2300/00

摘要： Disclosed herein are methods for enhancing the efficacy of epigallocatechin gallate (“EGCg”) in mitigating skeletal muscle loss in a subject. Providing EGCg to a subject in a nutritional composition reduces muscle protein degradation, thereby mitigating skeletal muscle loss in the subject. The combination of EGCg with zinc in a nutritional composition enhances the mitigating effect that EGCg has on muscle loss. Specifically, when used in combination, a nutritional composition containing both EGCg and zinc requires less EGCg to obtain the same mitigating effect that occurs in the same nutritional composition containing EGCg but no zinc.

公开(公告)号：US09650415B2

公开(公告)日：2017-05-16

申请号：US14787677

申请日：2014-06-20

申请人： Suntory Holdings Limited

发明人： Toshihide Suzuki ,  Shinya Fukizawa ,  Yoshinori Beppu ,  Hiroshi Watanabe

IPC分类号： A61K38/05 ,  C07K5/12 ,  C07K5/065 ,  A61K38/01 ,  C07K5/062 ,  A61K38/00

CPC分类号： C07K5/06078 ,  A61K38/00 ,  A61K38/011 ,  A61K38/05 ,  C07K5/06026 ,  C07K5/12

摘要： A uric acid-lowering agent containing, as an active ingredient, a tyrosine-containing cyclic dipeptide selected from the group consisting of cyclotryptophanyltyrosine, cycloseryltyrosine, cycloprolyltyrosine, cyclotyrosylglycine, cyclotyrosyltyrosine, cyclophenylalanyltyrosine, cycloleucyltyrosine, cyclolysyltyrosine, cyclohistidyltyrosine, cycloalanyltyrosine, cycloglutamyltyrosine, cyclovalyltyrosine, cycloisoleucyltyrosine, cyclothreonyltyrosine, cycloaspartyltyrosine, cycloasparaginyltyrosine, cycloglutaminyltyrosine, cycloarginyltyrosine, cyclomethionyltyrosine, and cyclotyrosylcysteine, or a salt thereof. The uric acid-lowering agent of the present invention has an excellent action of lowering a uric acid level, and the uric acid-lowering agent is useful in, for example, prevention or treatment of hyperuricemia, gout or the like.

公开(公告)号：US20160243202A1

公开(公告)日：2016-08-25

申请号：US14661526

申请日：2015-03-18

申请人： International Nutrition Research Company

发明人： Claude Vincent

IPC分类号： A61K38/44 ,  A61K31/405 ,  A61K31/145 ,  A61K31/715 ,  A61K31/733 ,  A61K38/16 ,  A61K31/59 ,  A61K31/519 ,  A61K31/675 ,  A61K31/355 ,  A61K31/202 ,  A61K31/14 ,  A61K31/198 ,  A61K31/714

CPC分类号： A61K38/446 ,  A23L29/25 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23L33/17 ,  A23L33/175 ,  A23L33/185 ,  A23L33/20 ,  A23L33/30 ,  A23L33/40 ,  A61K31/12 ,  A61K31/14 ,  A61K31/145 ,  A61K31/185 ,  A61K31/198 ,  A61K31/202 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/59 ,  A61K31/675 ,  A61K31/714 ,  A61K31/715 ,  A61K31/733 ,  A61K33/00 ,  A61K35/20 ,  A61K36/48 ,  A61K36/74 ,  A61K36/88 ,  A61K38/011 ,  A61K38/018 ,  A61K38/063 ,  A61K38/168 ,  A61K38/44 ,  C12Y111/01006 ,  C12Y115/01001 ,  A61K2300/00

摘要： The invention relates to an orally administered drug or medical nutrition composition for use in the prevention or treatment of metabolic steatosis and steatohepatitis of abdominally obese people with metabolic syndrome.The composition comprises at least: proteins and/or free amino adds, fibers selected at least from acacia gum fibers and/or fructooligosaccharide fibers, vitamins D, B6, B9, B12 and E, omega 3 in the form of ALA, glutathione, SOD, catalase, choline.

摘要翻译： 本发明涉及用于预防或治疗具有代谢综合征的腹部肥胖人的代谢脂肪变性和脂肪性肝炎的口服药物或医疗营养组合物。 所述组合物至少包含：至少从阿拉伯树胶纤维和/或低聚果糖纤维中选择的蛋白质和/或游离氨基添加剂，ALA，谷胱甘肽，SOD形式的维生素D，B6，B9，B12和E，ω3 ，过氧化氢酶，胆碱。

公开(公告)号：US09345747B2

公开(公告)日：2016-05-24

申请号：US14359504

申请日：2012-01-30

申请人： Filippo Bastia ,  Maurizio Saccomanno

发明人： Filippo Bastia ,  Maurizio Saccomanno

IPC分类号： A61K36/18 ,  A61K38/16 ,  A61K31/716 ,  A61K36/185 ,  A61K9/00 ,  A61K47/10 ,  A61K47/36 ,  A61K38/01

CPC分类号： A61K38/168 ,  A61K9/0031 ,  A61K31/716 ,  A61K36/185 ,  A61K38/011 ,  A61K47/10 ,  A61K47/36 ,  A61K2300/00

摘要： The present invention relates to a composition comprising at least one protein extract of hibiscus and/or at least one beta glucan or a salt thereof. Furthermore, the present invention relates to the use of said composition for the treatment of anal rhagades.

摘要翻译： 本发明涉及包含至少一种芙蓉蛋白提取物和/或至少一种β-葡聚糖或其盐的组合物。 此外，本发明涉及所述组合物用于治疗肛门痛的用途。

公开(公告)号：US09220752B2

公开(公告)日：2015-12-29

申请号：US14353605

申请日：2012-10-25

申请人： INTERNATIONAL NUTRITION RESEARCH COMPANY

发明人： Claude Vincent

IPC分类号： A61K47/00 ,  A61K38/17 ,  A23L1/305 ,  A23L2/66 ,  A61K31/185 ,  A61K31/198 ,  A61K31/202 ,  A61K31/355 ,  A61K31/405 ,  A61K31/519 ,  A61K31/59 ,  A61K31/675 ,  A61K33/06 ,  A61K33/24 ,  A61K33/30 ,  A61K38/01

CPC分类号： A61K38/1709 ,  A23L2/66 ,  A23L33/18 ,  A23L33/19 ,  A23V2002/00 ,  A61K31/185 ,  A61K31/198 ,  A61K31/202 ,  A61K31/355 ,  A61K31/405 ,  A61K31/519 ,  A61K31/59 ,  A61K31/675 ,  A61K33/06 ,  A61K33/24 ,  A61K33/30 ,  A61K38/011

摘要： An orally administered dietary product intended to reduce an obese person's visceral fat during the pre-operative phase prior to bariatric surgery, the product includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or a concentrate of whey, and calcium caseinate.

摘要翻译： 口服给药的饮食产品旨在在减肥手术之前的术前期间减少肥胖者的内脏脂肪，该产品特别包括以下混合物：分子量为200至10,000道尔顿的乳清水解产物，分离物和 /或乳清浓缩物和酪蛋白酸钙。